Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial

The Lancet Psychiatry

Volumn 7, Issue 6, 2020, Pages 515-527

  Husain, Muhammad Ishrat ^a   Chaudhry, Imran B ^b,c,d,e   Khoso, Ameer B ^c   Husain, Muhammad Omair ^a   Hodsoll, John ^f   Ansari, Moin A ^g   Naqvi, Haider A ^d   Minhas, Fareed A ^h   Carvalho, Andre F ^a   Meyer, Jeffrey H ^a   Deakin, Bill ^b   Mulsant, Benoit H ⁱ   Husain, Nusrat ^b   Young, Allan H ^f  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Pakistan Institute of Learning and Living   (Pakistan)

^d DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^e ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES   (Pakistan)

^h RAWALPINDI MEDICAL COLLEGE   (Pakistan)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CELECOXIB; ESCITALOPRAM; MINOCYCLINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; PLACEBO; PRESCRIPTION DRUG; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID; ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; AUTOMUTILATION; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-5; FACTORIAL DESIGN; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MEDICATION COMPLIANCE; MENTAL HOSPITAL; MENTAL PATIENT; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PAKISTAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRAFFIC ACCIDENT; BIPOLAR DISORDER; CASE CONTROL STUDY; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPIDEMIOLOGY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CELECOXIB; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PAKISTAN; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 85084753346     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(20)30138-3     Document Type: Article

References (41)

1. Merikangas, KR, Akiskal, HS, Angst, J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64 (2007), 543–552.
2. Goodwin, GM, Haddad, PM, Ferrier, IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.
3. Yatham, LN, Kennedy, SH, Parikh, SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 (2018), 97–170.
4. Geddes, JR, Miklowitz, DJ, Treatment of bipolar disorder. Lancet 381 (2013), 1672–1682.
5. Rao, JS, Harry, GJ, Rapoport, SI, Kim, HW, Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 15 (2010), 384–392.
6. Giridharan, VV, Sayana, P, Pinjari, OF, et al. Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review. Mol Psychiatry 25 (2020), 94–113.
7. Haarman, BC, Riemersma-Van der Lek, RF, de Groot, JC, et al. Neuroinflammation in bipolar disorder—a [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 40 (2014), 219–225.
8. Fiedorowicz, JG, Prossin, AR, Johnson, CP, Christensen, GE, Magnotta, VA, Wemmie, JA, Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord 187 (2015), 172–178.
9. Perugi, G, Quaranta, G, Belletti, S, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord 170 (2015), 95–103.
10. Sutterland, AL, Fond, G, Kuin, A, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 132 (2015), 161–179.
11. Goldstein, BI, Bipolar disorder and the vascular system: mechanisms and new prevention opportunities. Can J Cardiol 33 (2017), 1565–1576.
12. Husain, MI, Strawbridge, R, Stokes, PR, Young, AH, Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol 31 (2017), 1137–1148.
13. Rosenblat, JD, Kakar, R, Berk, M, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 18 (2016), 89–101.
14. Soczynska, JK, Mansur, RB, Brietzke, E, et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 235 (2012), 302–317.
15. Murrough, JW, Huryk, KM, Mao, X, et al. A pilot study of minocycline for the treatment of bipolar depression: effects on cortical glutathione and oxidative stress in vivo. J Affect Disord 230 (2018), 56–64.
16. Soczynska, JK, Kennedy, SH, Alsuwaidan, M, et al. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord 19 (2017), 198–213.
17. Yermakova, A, O'Banion, MK, Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6 (2000), 1755–1776.
18. Guo, JY, Li, CY, Ruan, YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612 (2009), 54–60.
19. Nery, FG, Monkul, ES, Hatch, JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23 (2008), 87–94.
20. Edberg, D, Hoppensteadt, D, Walborn, A, Fareed, J, Sinacore, J, Halaris, A, Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res 102 (2018), 1–7.
21. Hamilton, M, A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960), 56–62.
22. Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:suppl 20 (1998), 22–33.
23. Demissie, M, Hanlon, C, Birhane, R, Ng, L, Medhin, G, Fekadu, A, Psychological interventions for bipolar disorder in low- and middle-income countries: systematic review. BJPsych Open 4 (2018), 375–384.
24. Hamilton, M, Rating depressive patients. J Clin Psychiatry 41 (1980), 21–24.
25. Busner, J, Targum, SD, The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4 (2007), 28–37.
26. Kroenke, K, Spitzer, RL, Williams, JB, The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16 (2001), 606–613.
27. Spitzer, RL, Kroenke, K, Williams, JB, Löwe, B, A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166 (2006), 1092–1097.
28. Rabin, R, de Charro, F, EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33 (2001), 337–343.
29. Husain, N, Chaudhry, N, Fatima, B, et al. Antidepressant and group psychosocial treatment for depression: a rater blind exploratory RCT from a low income country. Behav Cogn Psychother 42 (2014), 693–705.
30. Husain, MI, Chaudhry, IB, Husain, N, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol 31 (2017), 1166–1175.
31. Faries, D, Herrera, J, Rayamajhi, J, DeBrota, D, Demitrack, M, Potter, WZ, The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34 (2000), 3–10.
32. Walters, SJ, Jacques, RM, Dos Anjos Henriques-Cadby, IB, Candlish, J, Totton, N, Xian, MTS, Sample size estimation for randomised controlled trials with repeated assessment of patient-reported outcomes: what correlation between baseline and follow-up outcomes should we assume?. Trials, 20, 2019, 566.
33. Mackinnon, A, The use and reporting of multiple imputation in medical research—a review. J Intern Med 268 (2010), 586–593.
34. Allison, PD, Missing data. Millsap, RE, Maydeu-Olivares, A, (eds.) The Sage handbook of quantitative methods in psychology, 2009, Sage Publications, London, 72–89.
35. Savitz, JB, Teague, TK, Misaki, M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2 × 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry, 8, 2018, 27.
36. McIntyre, RS, Subramaniapillai, M, Lee, Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry, 76, 2019, 783.
37. Osimo, EF, Baxter, LJ, Lewis, G, Jones, PB, Khandaker, GM, Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med 49 (2019), 1958–1970.
38. Berk, M, Copolov, DL, Dean, O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 64 (2008), 468–475.
39. Bowden, CL, A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 84 (2005), 117–125.
40. Li, F, Nasir, M, Olten, B, Bloch, MH, Meta-analysis of placebo response in adult antidepressant trials. CNS Drugs 33 (2019), 971–980.
41. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 62: 65–71.